MWMartin Wehling

Martin Wehling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Wehling has a total of 203 co-authors. Here are the top co-authors by number of shared publications:

  • Farhad Pazan

    Ehemals Institut für Klinische Pharmakologie, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland

    22 shared publications
  • Christel Weiss

    Department of Medical Statistics, Biomathematics and Information Processing, Medical Faculty, University of Heidelberg, Mannheim, Germany

    17 shared publications
  • Heinrich Burkhardt

    IV. Medical Department, Geriatrics, University Hospital Mannheim, Heidelberg University, Mannheim, Germany

    9 shared publications
  • Antonio Cherubini

    Geriatria, Accettazione geriatrica e Centro di ricerca per l’invecchiamento, IRCCS INRCA, Ancona, Italy

    4 shared publications
  • Forta

    4 shared publications
  • Helmut Frohnhofen

    Klinik für Orthopädie und Unfallchirurgie/Altersmedizin, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland

    4 shared publications

Latest Publications

  • Open Access

    Neurexan Prescription Is Associated with Lower Risk of Sleep Disorder Recurrence and Depression Prevalence as Compared to Z-Drugs and Benzodiazepines: A Retrospective Database Analysis in Germany

    by Göran Hajak, Céline Vetter, Martin Wehling

    Real-world evidence on the association between natural medicinal products and the recurrence of sleep disorders is currently limited, particularly when compared to the evidence reported for prescription hypnotics. In a retrospective cohort analysis, we investigated patients with sleep disorders prescribed either the natural medicinal product Neurexan (Nx4), benzodiazepines, or nonbenzodiazepines (Z-drugs) using the IQVIA Disease Analyzer database, which encompasses electronic medical records nationwide in Germany. A 1:1 matching procedure based on age, sex, prevalent depression, anxiety or adjustment disorder, and the number of medical consultations in the past 12 months resulted in four cohorts: patients prescribed Nx4 were matched with those prescribed Z-drugs (two cohorts with 8594 matched patients each), and another cohort of patients prescribed Nx4 were matched with those prescribed benzodiazepines (7779 matched pairs). Results from multivariable-adjusted Cox regression models demonstrated that Nx4 was associated with a significantly lower risk of recurrent sleep disorder diagnosis within 30–365 days after prescription compared to both Z-drugs (HR = 0.65, 95%CI = 0.60–0.70, p < 0.001) and benzodiazepines (HR = 0.85, 95%CI = 0.79–0.93, p < 0.001). Additionally, Nx4 was associated with a lower prevalence of depression compared to Z-drugs (HR = 0.90, 95%CI = 0.83–0.98, p = 0.020) and benzodiazepines (HR = 0.89, 95%CI = 0.82–0.97, p = 0.009). These findings suggest an association between Nx4 and improved sleep and mental health outcomes. However, due to inherent limitations in the study design, the causality of this relationship cannot be stated.

  • Die FORTA (Fit fOR The Aged) Liste

    by Farhad Pazan, Martin Wehling

    Zusammenfassung Hintergrund Multimorbidität und die daraus resultierende Polypharmazie sind bei Hochbetagten weit verbreitet, Evidenz zur Wirksamkeit und Sicherheit von Arzneimitteln bei älteren Menschen ist spärlich. Leitliniengesteuert führt dies häufig zu unangemessenen Verordnungen und arzneimittelbezogenen Problemen. Material und Methoden Zur Abhilfe wurden zahlreiche Listenansätze als Instrumente zur Optimierung der Medikation entwickelt. Diese Ansätze können in arzneimittelorientierte Listenansätze („drug-oriented listing approaches“ [DOLA]) wie die Beers Criteria®, eine Liste potenziell ungeeigneter Medikamente für ältere Menschen, oder in patientenorientierte Listenansätze („patient-in-focus listing approaches“ [PILA]) wie die Fit-fOR-The-Aged(FORTA)-Liste unterteilt werden. Ergebnisse Die neueste Version der FORTA-Liste wurde 2022 publiziert und enthält 299 Arzneimittel bzw. Wirkstoffgruppen, die auf 30 altersrelevante Indikationen ausgerichtet sind. Daneben wurden mehrere länder- oder regionalspezifische FORTA-Listen wie die EURO-FORTA-Liste entwickelt. Sehr wenige randomisierte, kontrollierte Studien belegen den Nutzen der bestehenden Listenansätze für die Verbesserung von klinischen Endpunkten wie unerwünschten Arzneimittelwirkungen, Stürzen oder Krankenhausaufenthalten. In der VALFORTA-Studie führte der Einsatz von FORTA zu einer signifikanten Verbesserung der Arzneimitteltherapie. Außerdem wurden wichtige klinische Endpunkte wie das Auftreten unerwünschter Arzneimittelwirkungen („number needed to treat“ = 5), die Aktivitäten des täglichen Lebens und die Sturzhäufigkeit durch die FORTA-Intervention signifikant und klinisch relevant verbessert. Schlussfolgerung Daher wird die Verwendung der FORTA-Liste zur Medikationsoptimierung bei älteren Patienten empfohlen. Anwendungsvoraussetzung ist die Arzneimittelbedarfsanalyse nach Diagnosen, Schweregrad, Lebenserwartung, funktionellem Zustand und Patientenwunsch.


  • Open Access

    Translatability scoring in prospective and retrospective COVID drug development cases

    by Alexandra Wendler, Martin Wehling

    Background: The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 has led to an enormous surge of clinical research. So far, the speed and success rate of related drug development projects, especially of vaccines, is unprecedented. For the first time, this situation allowed for the opportunistic evaluation of a translatability score, originally proposed in 2009, in a prospective manner. Methods: Several vaccines and treatments under development in clinical phase III trials were selected for translational scoring with the translatability score. Six prospective and six retrospective case studies were performed. The scores had to be determined for a fictive date before any results of the phase III trial were reported in any media. Spearman correlation analysis and a Kruskal Wallis test were performed for statistical evaluation. Results: A significant correlation between the translatability scores and the clinical outcomes in translation was found, as judged on the basis of positive/intermediate/negative endpoint studies or market approval. The Spearman correlation analysis of all cases (r = 0.91, p < 0.001), the prospective cases alone (r = 0.93, p = 0.008), and the retrospective cases alone (r = 0.93, p = 0.008) showed a strong correlation between the score and outcome; R2 demonstrated a score-derived determination of outcomes by 86%. Conclusions: The score detects strengths and weaknesses of a given project, resulting in the opportunity of selective amelioration of a project, as well as prospective portfolio risk balancing. Its substantial predictive value that has been demonstrated here for the first time could be of particular interest for biomedical industry (pharmaceutical and device manufacturers), funding agencies, venture capitalists, and researchers in the area. Future evaluations will have to address the generalizability of results obtained in an exceptional pandemic situation, and the potential adaptations of weighing factors/items to particular therapeutic areas.


  • Open Access

    A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

    by Farhad Pazan, Mirko Petrovic, Antonio Cherubini, Alfonso J. Cruz-Jentoft, Michael Denkinger, Tischa J. M. van der Cammen, Jennifer M. Stevenson, Kinda Ibrahim, Chakravarthi Rajkumar, Marit Stordal Bakken, et al.

    Background Cognitive decline is common in older people. Numerous studies point to the detrimental impact of polypharmacy and inappropriate medication on older people’s cognitive function. Here we aim to systematically review evidence on the impact of medication optimisation and drug interventions on cognitive function in older adults. Methods A systematic review was performed using MEDLINE and Web of Science on May 2021. Only randomised controlled trials (RCTs) addressing the impact of medication optimisation or pharmacological interventions on quantitative measures of cognitive function in older adults (aged > 65 years) were included. Single-drug interventions (e.g., on drugs for dementia) were excluded. The quality of the studies was assessed by using the Jadad score. Results Thirteen studies met the inclusion criteria. In five studies a positive impact of the intervention on metric measures of cognitive function was observed. Only one study showed a significant improvement of cognitive function by medication optimisation. The remaining four positive studies tested methylphenidate, selective oestrogen receptor modulators, folic acid and antipsychotics. The mean Jadad score was low (2.7). Conclusion This systematic review identified a small number of heterogenous RCTs investigating the impact of medication optimisation or pharmacological interventions on cognitive function. Five trials showed a positive impact on at least one aspect of cognitive function, with comprehensive medication optimisation not being more successful than focused drug interventions. More prospective trials are needed to specifically assess ways of limiting the negative impact of certain medication in particular and polypharmacy in general on cognitive function in older patients.


  • Open Access

    Higher FORTA (Fit fOR The Aged) scores are associated with poor functional outcomes, dementia, and mortality in older people

    by Farhad Pazan, Hanna Breunig, Christel Weiss, Susanne Röhr, Melanie Luppa, Michael Pentzek, Horst Bickel, Dagmar Weeg, Siegfried Weyerer, Birgitt Wiese, et al.

    Purpose: Higher Fit fOR The Aged (FORTA) scores have been shown to be negatively associated with adverse clinical outcomes in older hospitalized patients. This has not been evaluated in other health care settings. The aim of this study was to examine the association of the FORTA score with relevant outcomes in the prospective AgeCoDe–AgeQualiDe cohort of community-dwelling older people. In particular, the longitudinal relation between the FORTA score and mortality and the incidence of dementia was evaluated. Methods: Univariate and multivariate correlations between the FORTA score and activities of daily living (ADL) or instrumental activities of daily living (IADL) as well as comparisons between high vs. low FORTA scores were conducted. Results: The FORTA score was significantly correlated with ADL/IADL at baseline and at all follow-up visits (p < 0.0001). ADL/IADL results of participants with a low FORTA score were significantly better than in those with high FORTA scores (p < 0.0001). The FORTA score was also significantly (p < 0.0001) correlated with ADL/IADL in the multivariate analysis. Moreover, the mean FORTA scores of participants with dementia were significantly higher (p < 0.0001) than in those without dementia at follow-up visits 6 through 9. The mean FORTA scores of participants who died were significantly higher than those of survivors at follow-up visits 7 (p < 0.05), 8 (p < 0.001), and 9 (p < 0.001). Conclusion: In this study, an association between higher FORTA scores and ADL as well as IADL was demonstrated in community-dwelling older adults. Besides, higher FORTA scores appear to be linked to a higher incidence of dementia and even mortality.


  • Open Access

    The Sex-Specific Impact of the FORTA (Fit-fOR-The-Aged) List on Medication Quality and Clinical Endpoints in Older Hospitalized Patients: Secondary Analysis of a Randomized Controlled Trial

    by Ann-Kathrin Schmitt, Christel Weiss, Heinrich Burkhardt, Helmut Frohnhofen, Martin Wehling, Farhad Pazan

    Background Little is known about the sex-specific impact of drug optimization tools such as the Fit fOR The Aged (FORTA) list on drug use and relevant clinical endpoints in older people. Objective We aimed to detect gender differences of interventional effects on medication quality and related clinical effects in the VALFORTA trial. Patients and methods A sex-specific analysis of data from 409 patients (147 men and 262 women, mean age 79.4 and 82.7 years, respectively) in acute geriatric care comparing the control and FORTA intervention groups was performed. Changes of the FORTA score (sum of over- and undertreatment errors per patient), the incidence of adverse drug events (ADEs) during hospitalization, and several clinically relevant endpoints [e.g., the Barthel index (BI)] were tested for equivalence at a 20% margin. “Success” or “failure” for the development of these clinical endpoints was defined and their frequencies compared by a risk reduction analysis. Results Sex differences were insignificant for the reduction of the FORTA score, the improvement of BI, or over- and undertreatment errors (p > 0.05). In women only, the FORTA intervention significantly increased the number of patients without an ADE (p = 0.010). Statistical sex equivalence was found for the improvement of the FORTA scores, BI, and the number of prevented events (e.g., falls, confusion, or renal failure) (p < 0.05), but not for the improvement of specific mistreatments or over- and undertreatment scores under altered inclusion criteria (p > 0.05). Conclusions Both sexes benefit equally from the FORTA intervention regarding the amelioration of the quality of drug treatment as well as several clinically relevant outcomes. In addition, the positive impact of the FORTA intervention on the number of adverse drug events appears to be greater in women. Trial Registration Number DRKS00000531.